Management of venous leg ulcers with a lipidocolloid matrix impregnated with NOSF (Nano-Oligosaccharide Factor) Results of a clinical study

P. Leger (1), F. Vin (2), H. Paradis (3), J.-P. Gobin (4), O. Tacca (5), S. Bohbot (5) and al.

(1) Service Médecine Vasculaire, Clinique Pasteur, Toulouse, France
(2) Cabinet de Phlébo-angiologie, Neuilly-sur-Seine, France
(3) Service Médecine vasculaire, CH d’Auch, Auch, France
(4) Cabinet d’Angéiologie-Médecine Vasculaire, Lyon, France
(5) Laboratoires URGO, Chenôve, France

INTRODUCTION

The Nano-Oligosaccharide Factor (NOSF) is a new compound aiming to promote wound closure mainly through inhibition of Matrix Metalloproteinases (MMPs) present in excess in chronic wounds. This factor is incorporated within a lipid-colloid matrix (TLC-NOSF matrix) and locally released in the wound.

AIM

The objective of this study was to assess the efficacy and the tolerance of a new lipidocolloid dressing impregnated with NOSF * in the local management of venous leg ulcers.

METHODS

This study was a prospective, phase III, multicenter (12 centers), non-comparative clinical trial. Patients were followed-up six weeks and assessed on a regular basis (5 clinical evaluations at baseline, D7, D14, D28 and D42), including clinical evaluation, area tracings and photographs. Area of the venous leg ulcers (abpi ≥ 0.8) was ranged from 3 to 50 cm² with a granulation tissue recovering more than 50 % of the wound bed. The percentage of the wound area relative reduction (%RR) was the primary efficacy criterion of this study.

RESULTS

Twenty two patients were selected and treated for a 6 weeks period. Mean wound area at baseline was 9.09 cm² and was reduced by an average of 56% at the end of treatment. Complete healing was obtained in 3 patients in an average time of 4 weeks. Four local adverse events considered to be in relation with the tested dressing, occurred during the study.

CONCLUSION

The new lipid-colloid dressing impregnated with NOSF *, in association with compression therapy, improved the healing of venous leg ulcers.

* Brand name: the new lipid-colloid absorbant dressing impregnated with TLC-NOSF is Urgocell Start Contact from Laboratoires Urgo